Richard Chin

Richard Chin, listed as chief executive, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Kindred Biosciences, Inc., Oncotelic Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. We count 78 filings; the first trade dates from 1 August 2006 and the latest from 18 August 2026.

Market trades split into 14 purchases (€198k) and 25 sales (€6.0M). The net balance comes to €5.8M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 17 share grants and 15 option exercises.

Half of the purchases are above €9,273 and half below.

The latest filing, published on 20 August 2026, reports an option exercise in Cytek Biosciences, Inc. The most recent open-market purchase was published on 18 September 2006, 7,356 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.